GlassScriptPhysician profile
Leo L Wang
NPI 1548898372
$2,703.39
in general payments reported to CMS, 2019-2025
15 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $81.03 · 2024: $1,273 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,203 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,203.39 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $778.58 | 2024-2025 | Tremfya |
| Endo USA, INC. | $500.00 | 2025 | |
| Sun Pharmaceutical Industries INC. | $377.69 | 2024-2025 | |
| Abbvie INC. | $317.24 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $212.36 | 2024-2025 | Tremfya |
| Ucb, INC. | $106.92 | 2024-2025 | Bimzelx |
| Incyte Corporation | $105.03 | 2024 | Opzelura |
| Pfizer INC. | $81.03 | 2023 | |
| Galderma Laboratories, L.P. | $73.40 | 2024-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $40.10 | 2025 | |
| Convatec INC. | $34.36 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $27.98 | 2024 | Dupixent |
| Lnhc, INC | $19.23 | 2025 | Zelsuvmi |
| Lilly USA, LLC | $16.33 | 2024 | Zepbound, Taltz |
| Helsinn Therapeutics (U.S.), INC. | $13.14 | 2024 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.